Workflow
天坛生物(600161) - 2016 Q1 - 季度财报
BTBPBTBP(SH:600161)2016-04-29 16:00

Financial Performance - Operating revenue for the first quarter was CNY 360,171,437.81, representing a year-on-year increase of 1.74%[5] - Net profit attributable to shareholders of the listed company was a loss of CNY 676,046.48, a decline of 105.59% compared to the same period last year[5] - The total profit for the company in Q1 2016 was 31,069,563.39 RMB, down 36.17% from the previous year, attributed to increased fixed costs and a decline in vaccine sales[15] - Net profit for the current period is ¥12,520,065.46, a decline of 61.8% compared to ¥32,798,360.67 in the previous period[25] - The net profit attributable to the parent company is a loss of ¥676,046.48, compared to a profit of ¥12,098,387.93 in the previous period[25] - Basic and diluted earnings per share are both -¥0.001, down from ¥0.02 in the previous period[25] Cash Flow - The net cash flow from operating activities was a negative CNY 5,894,416.21, worsening by 65.01% year-on-year[5] - Cash flow from operating activities shows a net outflow of ¥5,894,416.21, worsening from a net outflow of ¥3,572,079.63 in the previous period[31] - Total cash inflow from operating activities was 16,109,533.71 RMB, a decrease from 51,104,233.77 RMB in the same quarter last year, highlighting a drop in revenue generation[34] - The total cash outflow from operating activities was 117,889,737.28 RMB, down from 127,570,967.08 RMB year-over-year, suggesting improved operational efficiency[34] - Cash inflow from financing activities totaled 285,900,836.83 RMB, significantly higher than 73,189,821.74 RMB in the previous year, reflecting increased borrowing activities[35] - The cash flow from financing activities resulted in a net increase of 179,262,445.62 RMB, contrasting with a net decrease of -43,986,907.72 RMB in the previous year, showing improved financing conditions[35] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,628,114,060.70, a decrease of 0.07% compared to the end of the previous year[5] - Current liabilities totaled CNY 1,437,419,403.64, compared to CNY 1,422,928,561.57 at the start of the year, reflecting a marginal increase[19] - Non-current liabilities decreased from CNY 1,972,758,274.53 to CNY 1,941,935,002.56, indicating a reduction of approximately 1.56%[19] - The company's total liabilities were CNY 3,379,354,406.20, slightly down from CNY 3,395,686,836.10[19] - Owner's equity totaled CNY 2,248,759,654.50, an increase from CNY 2,236,239,589.04, representing a growth of about 0.57%[19] Shareholder Information - The total number of shareholders at the end of the reporting period was 28,994[10] - The largest shareholder, China Biotechnology Co., Ltd., held 274,725,000 shares, accounting for 53.3% of the total shares[10] Operational Changes - The company is actively working on integrating its businesses and plans to establish Tian Tan Bio as the sole blood product business platform under China Biotechnology Corporation by March 15, 2018[16] - The company is undergoing asset transfers and regulatory compliance to eliminate competition with its subsidiaries, enhancing operational transparency[16] Inventory and Receivables - The company reported a significant increase in other receivables, which rose by 119.52% to 40,325,716.95 RMB, mainly due to increased departmental loans and rental income[13] - Inventory levels rose to CNY 283,443,428.94 from CNY 266,045,146.39, reflecting an increase of about 6.5%[21] - The company reported a total current asset of CNY 934,120,360.25, up from CNY 855,216,778.44, indicating a growth of approximately 9.5%[21]